title: Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
authors.forename: Bunchoo
authors.initials: B
authors.lastname: Pongtanakul
authors.forename: Vip
authors.initials: V
authors.lastname: Viprakasit
mesh_terms: D001565:Benzoates / Q000008:administration & dosage*; D000077588:Deferasirox; D006801:Humans; D007502:Iron Chelating Agents / Q000008:administration & dosage*; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology*; D013789:Thalassemia / Q000150:complications* / Q000628:therapy; D065227:Transfusion Reaction; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox